Drug Guide
Acetazolamide Sodium
Classification
Therapeutic: Anticonvulsant, Diuretic, Carbonic Anhydrase Inhibitor
Pharmacological: Carbonic Anhydrase Inhibitor
FDA Approved Indications
- Glaucoma (ocular HTN)
- Edema associated with congestive heart failure or drug therapy
- Altitude sickness
- Epilepsy (adjunct)
- Metabolic alkalosis
Mechanism of Action
Inhibits carbonic anhydrase enzyme, leading to decreased hydrogen ion secretion at nephrons, resulting in diuresis and reduction in aqueous humor formation.
Dosage and Administration
Adult: Dose varies by indication; for glaucoma, usual starting dose is 250 mg twice daily, adjusted as needed.
Pediatric: Dose varies based on age and indication; consult specific protocols.
Geriatric: Start at lower doses due to increased risk of side effects.
Renal Impairment: Adjust dose; clearance is reduced, risking toxicity.
Hepatic Impairment: Use with caution; no specific adjustment specified.
Pharmacokinetics
Absorption: Well absorbed orally
Distribution: Widely distributed; crosses blood-brain barrier
Metabolism: Minimal hepatic metabolism
Excretion: Primarily renal excretion
Half Life: 10-15 hours in healthy adults
Contraindications
- Hypersensitivity to sulfonamides or acetazolamide
- Severe hepatic or respiratory acidosis
- Electrolyte imbalance (e.g., hyponatremia, hypokalemia)
Precautions
- Monitor electrolytes, renal function, and acid-base status regularly.
- Use with caution in patients with kidney or liver impairment, pregnancy, and lactation.
Adverse Reactions - Common
- Paresthesias (Common)
- Altered taste (Common)
- Polyuria (Common)
- Metabolic acidosis (Less common)
Adverse Reactions - Serious
- Agranulocytosis (Rare)
- Neutropenia (Rare)
- Electrolyte disturbances (hypokalemia, hyponatremia) (Less common)
- Allergic reactions including rash and Stevens-Johnson syndrome (Rare)
Drug-Drug Interactions
- Lithium (increased serum levels)
- Corticosteroids (electrolyte imbalances)
- Other diuretics
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor electrolyte levels, renal function, and for signs of metabolic acidosis.
Diagnoses:
- Electrolyte imbalance
- Risk for dehydration
- Risk for acid-base imbalance
Implementation: Administer with food or after meals if GI upset occurs; monitor laboratory values regularly.
Evaluation: Assess for therapeutic effects and adverse reactions, including intraocular pressure reduction and electrolyte stability.
Patient/Family Teaching
- Take medication exactly as prescribed.
- Report signs of electrolyte imbalance (muscle weakness, irregular heartbeat).
- Use sunscreen to prevent photosensitivity.
- Maintain adequate hydration.
Special Considerations
Black Box Warnings:
- None explicitly, but caution in use in patients with sulfa allergies.
Genetic Factors: Sulfa allergy history is relevant.
Lab Test Interference: May cause false increase in serum bicarbonate and glucose tests.
Overdose Management
Signs/Symptoms: Severe metabolic acidosis, electrolyte disturbances, sedation, coma.
Treatment: Supportive care, correction of electrolyte imbalances, possibly hemodialysis in severe cases.
Storage and Handling
Storage: Store at room temperature, protected from moisture and light.
Stability: Stable for 24 months when stored properly.